DANHEART (H-HeFT and Met-HeFT)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1100 participants.

Also called NCT03514108

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 1,100 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03514108
  • EudraCT 2015-002150-12
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03514108. Randomized; quadruple masking; primary purpose treatment. Start 2018-03-01 (actual); primary completion 2025-12-31 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
DANHEART (H-HeFT and Met-HeFT)
Acronym
DANHEART
Condition
Heart Failure
Condition
Diabetes
Intervention (Drug)
Hydralazine Isosorbide Dinitrate
Intervention (Drug)
Placebo Oral Tablet
Intervention (Drug)
Metformin Hydrochloride
Intervention (Drug)
Placebo Oral Tablet
Lead sponsor
Henrik Wiggers (class: other)
Collaborator
Danish Heart Foundation (class: other)
Collaborator
Danish Council for Independent Research (class: other)
Collaborator
The Danish Regions: Foundation for Medical Research (class: not stated)
Collaborator
Novo Nordisk Foundation (class: other)
Collaborator
The Aase og Ejnar Danielsen Foundation (class: not stated)

Record details

Record id
cardio:ct-nct03514108
Content hash
1113958da1e3af6b9ee67ec344e9b4fa905694e38e9efca67d2a67b70afdec59